BACKGROUND: Astrocytomas are the most common form of primary intracranial tumor; however, survival of patients with high-grade tumors has not changed much compared with that reported in the early 1970s. OBJECTIVE. Our objective was to assess the efficacy, security, and survival rate of postoperative chemotherapy with ifosfamide, carboplatin, and etoposide (ICE) in pediatric patients with anaplastic astrocytomas (AA) and glioblastoma multiforme (GM). METHODS: In a phase II study, we evaluated 25 children with AA or GM. The proposed treatment was four courses of chemotherapy with ICE followed by hyperfractionated radiotherapy, and then four more courses of ICE. Patients were evaluated using MRI after surgery, after the second course of chemotherapy, and again after the last. Toxicity was determined before each course. RESULTS: The overall and disease-free survival at 60 months was 67% and 56% respectively. For supratentorial localization it was 92% at 60 months and 20% at 18 months for brain stem tumors. Fourteen patients had a complete response and 9 died as a result of tumor progression. CONCLUSIONS: Postoperative chemotherapy with ICE reduces the tumor size and increases the survival rate of pediatric patients with malignant astrocytomas with minimal toxicity.
BACKGROUND:Astrocytomas are the most common form of primary intracranial tumor; however, survival of patients with high-grade tumors has not changed much compared with that reported in the early 1970s. OBJECTIVE. Our objective was to assess the efficacy, security, and survival rate of postoperative chemotherapy with ifosfamide, carboplatin, and etoposide (ICE) in pediatric patients with anaplastic astrocytomas (AA) and glioblastoma multiforme (GM). METHODS: In a phase II study, we evaluated 25 children with AA or GM. The proposed treatment was four courses of chemotherapy with ICE followed by hyperfractionated radiotherapy, and then four more courses of ICE. Patients were evaluated using MRI after surgery, after the second course of chemotherapy, and again after the last. Toxicity was determined before each course. RESULTS: The overall and disease-free survival at 60 months was 67% and 56% respectively. For supratentorial localization it was 92% at 60 months and 20% at 18 months for brain stem tumors. Fourteen patients had a complete response and 9 died as a result of tumor progression. CONCLUSIONS: Postoperative chemotherapy with ICE reduces the tumor size and increases the survival rate of pediatric patients with malignant astrocytomas with minimal toxicity.
Authors: V A Levin; J H Uhm; K A Jaeckle; A Choucair; P J Flynn; M D Prados; J M Bruner; S M Chang; A P Kyritsis; M J Gleason; K R Hess Journal: Clin Cancer Res Date: 2000-10 Impact factor: 12.531
Authors: J L Finlay; S Goldman; M C Wong; M Cairo; J Garvin; C August; B H Cohen; P Stanley; R A Zimmerman; B Bostrom; J R Geyer; R E Harris; J Sanders; A J Yates; J M Boyett; R J Packer Journal: J Clin Oncol Date: 1996-09 Impact factor: 44.544
Authors: R L Heideman; E C Douglass; R A Krance; J Fontanesi; J A Langston; R A Sanford; E H Kovnar; J Ochs; J Kuttesch; J J Jenkins Journal: J Clin Oncol Date: 1993-08 Impact factor: 44.544
Authors: Aleksandra Napieralska; Aleksandra Krzywon; Agnieszka Mizia-Malarz; Joanna Sosna-Zielińska; Ewa Pawłowska; Małgorzata A Krawczyk; Katarzyna Konat-Bąska; Aneta Kaczorowska; Anna Dąbrowska; Maciej Harat Journal: Cancers (Basel) Date: 2021-04-24 Impact factor: 6.639